CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 34 enrolled
Drug / intervention
Secukinumab (AIN457)drug
Likely dose
Secukinumab (AIN457) 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02547714
NCT02547714Phase 4Completed
CompareCT.gov

A Multi-center, Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety for 16 Weeks in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine A

Novartis Pharmaceuticals·interventional·Posted Sep 11, 2015·Updated Sep 11, 2017

In Brief

A Phase 4 clinical trial evaluating Secukinumab (AIN457) for Plaque Psoriasis. Completed, enrolled 34 participants across 11 sites.

Detailed Summary

The purpose of this study was to assess the efficacy and safety of secukinumab at Week 16 based on psoriasis area and severity index (PASI) 75 in subjects who had inadequate response to cyclosporine A.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis
CountriesJapan
Collaborators--

Timeline

Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 11, 2015
Enrollment StartJun 16, 2015
Primary CompletionMay 2, 2016
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 10.8 years ago

Interventions

Secukinumab (AIN457)drug

Secukinumab was supplied as 150 mg doses, provided in 1 mL prefilled syringes.